OA12586A - Methods of treatment of a bcl-2 disorder using bcl-2 antisence oligomers. - Google Patents

Methods of treatment of a bcl-2 disorder using bcl-2 antisence oligomers. Download PDF

Info

Publication number
OA12586A
OA12586A OA1200300058A OA1200300058A OA12586A OA 12586 A OA12586 A OA 12586A OA 1200300058 A OA1200300058 A OA 1200300058A OA 1200300058 A OA1200300058 A OA 1200300058A OA 12586 A OA12586 A OA 12586A
Authority
OA
OAPI
Prior art keywords
bcl
cancer
dose
day
antisense oligomer
Prior art date
Application number
OA1200300058A
Other languages
English (en)
Inventor
Warrel Raymond P Jr
Robert E Klem
Howard Fingert
Original Assignee
Genta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27397795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA12586(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genta Inc filed Critical Genta Inc
Publication of OA12586A publication Critical patent/OA12586A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA1200300058A 2000-08-25 2001-08-23 Methods of treatment of a bcl-2 disorder using bcl-2 antisence oligomers. OA12586A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22797000P 2000-08-25 2000-08-25
US23700900P 2000-09-29 2000-09-29
US09/709,170 US7795232B1 (en) 2000-08-25 2000-11-10 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Publications (1)

Publication Number Publication Date
OA12586A true OA12586A (en) 2006-06-07

Family

ID=27397795

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200300058A OA12586A (en) 2000-08-25 2001-08-23 Methods of treatment of a bcl-2 disorder using bcl-2 antisence oligomers.

Country Status (33)

Country Link
US (2) US7795232B1 (cs)
EP (2) EP1313514B1 (cs)
JP (1) JP2004507480A (cs)
KR (1) KR20030034153A (cs)
CN (1) CN1471408A (cs)
AP (1) AP2003002761A0 (cs)
AT (1) ATE432717T1 (cs)
AU (2) AU8837301A (cs)
BG (1) BG107641A (cs)
BR (1) BR0113447A (cs)
CA (1) CA2419480A1 (cs)
CY (1) CY1109340T1 (cs)
CZ (1) CZ301582B6 (cs)
DE (1) DE60138892D1 (cs)
DK (1) DK1313514T3 (cs)
DZ (1) DZ3471A1 (cs)
EA (1) EA005424B1 (cs)
EE (1) EE200300074A (cs)
ES (1) ES2327904T3 (cs)
GE (1) GEP20063934B (cs)
HK (1) HK1056505A1 (cs)
HR (1) HRP20030102A2 (cs)
HU (1) HUP0303125A2 (cs)
IL (1) IL154409A0 (cs)
MX (1) MXPA03001575A (cs)
NO (1) NO20030858L (cs)
OA (1) OA12586A (cs)
PL (1) PL363050A1 (cs)
PT (1) PT1313514E (cs)
SK (1) SK3652003A3 (cs)
UA (1) UA77945C2 (cs)
WO (1) WO2002017852A2 (cs)
YU (1) YU13603A (cs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US7309692B1 (en) 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
EP2261368A1 (en) 2002-03-13 2010-12-15 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US7256284B2 (en) 2002-11-14 2007-08-14 Genta Incorporated Inhibitory oligonucleotides targeted to Bcl-2
AU2003295598B2 (en) 2002-11-15 2009-12-24 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
DE10258677A1 (de) * 2002-12-13 2004-06-24 Elez, Vera, Dr. Kombinations-antisense-Oligonukleotid-Krebstherapie
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2516553C (en) 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
JP4505749B2 (ja) 2003-05-30 2010-07-21 日本新薬株式会社 Ｂｃｌ−２の発現抑制をするオリゴ二本鎖ＲＮＡとそれを含有する医薬組成物
ES2787475T3 (es) 2003-06-24 2020-10-16 Genomic Health Inc Predicción de probabilidad de recurrencia del cáncer
CA2531967C (en) 2003-07-10 2013-07-16 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
ES2360113T3 (es) 2003-12-23 2011-06-01 Genomic Health, Inc. Amplificación universal de rna fragmentado.
GB0406415D0 (en) * 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
JP5813908B2 (ja) 2004-04-09 2015-11-17 ジェノミック ヘルス， インコーポレイテッド 化学療法剤に対する応答を予測するための遺伝子発現マーカー
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
AU2013203202B2 (en) * 2004-08-26 2017-02-16 Engeneic Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially derived intact minicells
SI2386640T1 (sl) * 2004-08-26 2015-06-30 Engeneic Molecular Delivery Pty Ltd Dostava funkcionalnih nukleinskih kislin celicam sesalcev preko bakterijsko izvirajočih, intaktnih minicelic
CA2585571C (en) 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
CA2585561C (en) 2004-11-05 2018-07-17 Genomic Health, Inc. Esr1, pgr, bcl2 and scube2 group score as indicators of breast cancer prognosis and prediction of treatment response
WO2007064857A2 (en) * 2005-12-01 2007-06-07 Pronai Therapeutics, Inc. Amphoteric liposome formulation
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
CN100368424C (zh) * 2006-07-21 2008-02-13 福建金山生物制药股份有限公司 抑制肿瘤的反义核苷酸
US20080171718A1 (en) * 2006-11-08 2008-07-17 Brown Bob D Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents
DE102007020554A1 (de) * 2007-04-27 2008-10-30 Henkel Ag & Co. Kgaa Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Behandlung epithelialen Deckgewebes
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
WO2009071681A2 (en) * 2007-12-07 2009-06-11 Santaris Pharma A/S Rna antagonist compounds for the modulation of bcl-2
CA2744031A1 (en) * 2008-11-21 2010-05-27 Isis Pharmaceuticals, Inc. Anticancer combination comprising docetaxel and an antisense oligonucleotide
PE20121495A1 (es) 2009-07-30 2012-11-19 Antisense Pharma Gmbh Combinacion de un agente quimioterapeutico y un inhibidor del sistema tgf-beta
JP5963680B2 (ja) * 2010-01-06 2016-08-03 カッパーアールエヌエー，インコーポレイテッド 膵臓発生遺伝子に対する天然アンチセンス転写物の阻害による膵臓発生遺伝子疾患の治療
SI3319995T1 (sl) * 2015-07-07 2019-07-31 F. Hoffmann-La Roche Ag Kombinirana terapija s konjugatom protitelo anti-HER-2 in zdravilo ter zaviralcem bcl-2
WO2017021963A1 (en) 2015-08-03 2017-02-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases
WO2021231486A1 (en) * 2020-05-13 2021-11-18 Unity Biotechnology, Inc. Cancer treatment by senescence induction followed by a senolytic

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5098890A (en) 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
EP0633934A1 (en) 1992-04-02 1995-01-18 Imperial Cancer Research Technology Limited Modified cells and method of treatment
JPH08506087A (ja) 1992-10-21 1996-07-02 テンプル ユニバーシティ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション ガン処置のための抗腫瘍薬とアンチセンスオリゴヌクレオチドの組み合わせ
US5550019A (en) 1993-05-26 1996-08-27 La Jolla Cancer Research Foundation Methods of identifying compounds which alter apoptosis
US5783683A (en) * 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression

Also Published As

Publication number Publication date
US20100216867A1 (en) 2010-08-26
NO20030858D0 (no) 2003-02-24
EP1313514A4 (en) 2005-07-13
CN1471408A (zh) 2004-01-28
US7795232B1 (en) 2010-09-14
ATE432717T1 (de) 2009-06-15
DK1313514T3 (da) 2009-10-12
PT1313514E (pt) 2009-09-01
UA77945C2 (en) 2007-02-15
AU2001288373B2 (en) 2006-05-11
CZ301582B6 (cs) 2010-04-21
WO2002017852A2 (en) 2002-03-07
BG107641A (bg) 2004-01-30
HRP20030102A2 (en) 2005-04-30
CZ2003848A3 (cs) 2003-11-12
BR0113447A (pt) 2003-07-08
AP2003002761A0 (en) 2003-06-30
YU13603A (sh) 2006-05-25
AU8837301A (en) 2002-03-13
CY1109340T1 (el) 2014-07-02
EA200300294A1 (ru) 2003-08-28
PL363050A1 (en) 2004-11-15
EP2135623A1 (en) 2009-12-23
MXPA03001575A (es) 2004-11-01
EE200300074A (et) 2004-12-15
DE60138892D1 (de) 2009-07-16
WO2002017852A3 (en) 2003-04-03
JP2004507480A (ja) 2004-03-11
NO20030858L (no) 2003-04-24
SK3652003A3 (en) 2003-08-05
ES2327904T3 (es) 2009-11-05
IL154409A0 (en) 2003-09-17
DZ3471A1 (fr) 2002-03-07
GEP20063934B (en) 2006-10-10
HUP0303125A2 (hu) 2003-12-29
KR20030034153A (ko) 2003-05-01
EP1313514A2 (en) 2003-05-28
HK1056505A1 (en) 2004-02-20
EP1313514B1 (en) 2009-06-03
EA005424B1 (ru) 2005-02-24
CA2419480A1 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
OA12586A (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisence oligomers.
AU2001288373A1 (en) Methods of treatment of a BCL-2 disorder using BCL-2 antisense oligomers
KR101697396B1 (ko) 결합 조직 성장 인자（ctgf）를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법
KR102339886B1 (ko) 연결 조직 성장 인자를 표적화하는 rna 복합체를 사용한 특발성 폐 섬유증의 치료 방법
KR20130137725A (ko) 5-아자-시토신이 내부에 삽입된 올리고뉴클레오티드 유사체
US20040147473A1 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
JP2011529501A (ja) アンチセンスオリゴヌクレオチドによるＴｏｌｌ様受容体９発現の調節
AU2009279855A1 (en) Modulation of toll-like receptor 8 expression by antisense oligonucleotides
CN113151261A (zh) 反义寡核苷酸作为tgf-r信号传导的抑制剂
EP2524038A1 (en) Modulation of transforming growth factor-beta 1 expression
EP0851919A1 (en) Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
WO2004056971A2 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US7662792B2 (en) Modulation of Fas and FasL expression
AU2009279834A1 (en) Modulation of toll-like receptor 7 expression by antisense oligonucleotides
JP6437930B2 (ja) 悪性胸膜中皮腫を治療するためのマイクロｒｎａを基にしたアプローチ
EP1597365B1 (en) Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
US7855183B2 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
AU2009313607A1 (en) Modulation of toll-like receptor 5 expression by antisense oligonucleotides
US7074768B2 (en) Modified protein kinase A-specific oligonucleotides and methods of their use
WO1998013072A1 (en) Compositions for and methods of treating multiple drug resistance
ZA200301161B (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers.
WO2005115480A2 (en) Modified protein kinase a-specific oligonucleotides and methods of their use